CIP
VRTX icon

Convergence Investment Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Convergence Investment Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,095
Closed -$441K – 311
2024
Q4 		$441K Buy
1,095
+573
+110% +$266K 0.1% 192
2024
Q3 		$243K Sell
522
-33
-6% -$15.9K 0.07% 217
2024
Q2 		$260K Sell
555
-751
-58% -$326K 0.08% 222
2024
Q1 		$546K Buy
1,306
+148
+13% +$62.6K 0.21% 124
2023
Q4 		$471K Sell
1,158
-163
-12% -$60.2K 0.25% 96
2023
Q3 		$459K Buy
1,321
+533
+68% +$186K 0.27% 93
2023
Q2 		$277K Sell
788
-709
-47% -$239K 0.16% 129
2023
Q1 		$472K Sell
1,497
-266
-15% -$79.8K 0.28% 97
2022
Q4 		$509K Sell
1,763
-5
-0.3% -$1.52K 0.3% 91
2022
Q3 		$512K Buy
1,768
+451
+34% +$130K 0.33% 87
2022
Q2 		$371K Buy
1,317
+120
+10% +$32.1K 0.22% 106
2022
Q1 		$312K Buy
+1,197
New +$284K 0.16% 132
2021
Q1 		– Sell
-1,379
Closed -$326K – 278
2020
Q4 		$326K Buy
+1,379
New +$316K 0.16% 129
2018
Q2 		– Sell
-14,920
Closed -$2.43M – 895
2018
Q1 		$2.43M Buy
14,920
+1,527
+11% +$249K 0.32% 119
2017
Q4 		$2.01M Sell
13,393
-563
-4% -$83.4K 0.27% 129
2017
Q3 		$2.12M Buy
13,956
+2,857
+26% +$430K 0.3% 127
2017
Q2 		$1.43M Buy
+11,099
New +$1.34M 0.21% 189

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Convergence Investment Partners's VRTX Position: Q1 2025 in Review

Convergence Investment Partners sold out of Vertex Pharmaceuticals (VRTX) in Q1 2025, closing a stake of 1,095 shares — an estimated $441K sold.

Convergence Investment Partners first reported a position in VRTX in Q2 2017 and held it in 17 quarters. The position peaked at $2.43M in Q1 2018. 1,617 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

  • Convergence Investment Partners reported no remaining Vertex Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Convergence Investment Partners sold 1,095 Vertex Pharmaceuticals shares in Q1 2025, an estimated $441K.
  • Convergence Investment Partners first reported a position in Vertex Pharmaceuticals in Q2 2017 and held it in 17 quarters.
  • Convergence Investment Partners's Vertex Pharmaceuticals position peaked at $2.43M in Q1 2018.
  • 1,617 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on Convergence Investment Partners's 13F filing for Q1 2025, filed 6 May 2025.